Join

Enter Details

Comment on stories, receive email newsletters & alerts.

@
This is your permanent identity for Business Insider Australia
Your email must be valid for account activation
Minimum of 8 standard keyboard characters

Subscribe

Email newsletters but will contain a brief summary of our top stories and news alerts.

Forgotten Password

Enter Details


Back to log in

This company's shares are on a tear after it discovered a way to help pigs with diarrhoea

The Pig Racing and Diving show at the Royal Melbourne Show. Scott Barbour/Getty Images

Shares in Anatara Lifesciences are on a tear after the developer of therapies for pig diarrhoea signed an exclusive license option agreement with Zoetis, a leading global animal health company.

A short time ago, the shares were up 8.5% to at $1.40, about three times the price of a year ago.

Under the agreement, Zoetis has the exclusive global right to evaluate potential applications of Detach, Anatara’s non-antibiotic treatment for diarrhoea, for veterinary use in production animals.

Anatara retains rights to the Australian and New Zealand markets.

Diarrhoea is a problem for pig farms, with sick pigs losing condition and piglets dying. Traditionally antibiotics are used to treat this. Australia processes almost 5 million pigs a year in an industry worth $1 billion.

Anatara raised $9 million in a share placement in July last year so the company could push into Europe, the US and Asia earlier than forecast.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.